Amgen Inc. on Monday announced several executive changes, with Chief Financial Officer Robert A. Bradway moving to the new position of chief operating officer beginning next month.

Bradway, 47, will also hold the title of president. He has been CFO and an executive vice president since April 2007, and joined the company in 2006 as vice president of operations strategy. He will start his new job on May 11.

“Bob Bradway is an outstanding executive with significant potential,” said Chief Executive Kevin Sharer in a statement. “He earned it.”

Bradway will be responsible for the company’s manufacturing operations, strategy & corporate development, information technology, global government affairs and compliance.

He also will take over global commercial operations from Executive Vice President George J. Morrow, who plans to retire on Jan. 31, 2011. In the interim, Morrow, 58, will report directly to Sharer on variety of strategic projects and be involved in the launch of Amgen’s new osteoporosis drug, Prolia, after it receives U.S. Food and Drug Administration approval. Morrow has been with Amgen since 2001.

Chief Accounting Officer Michael A. Kelly will serve as Amgen’s acting CFO until a permanent replacement for Bradway is announced.

Shares earlier closed down 45 cent, or less than 1 percent, to $58.43 on the Nasdaq.